These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 38715714)

  • 1. Neuroimaging and plasma evidence of early white matter loss in Parkinson's disease with poor outcomes.
    Zarkali A; Hannaway N; McColgan P; Heslegrave AJ; Veleva E; Laban R; Zetterberg H; Lees AJ; Fox NC; Weil RS
    Brain Commun; 2024; 6(3):fcae130. PubMed ID: 38715714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study.
    Mak E; Su L; Williams GB; Firbank MJ; Lawson RA; Yarnall AJ; Duncan GW; Owen AM; Khoo TK; Brooks DJ; Rowe JB; Barker RA; Burn DJ; O'Brien JT
    Brain; 2015 Oct; 138(Pt 10):2974-86. PubMed ID: 26173861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes of brain structure in Parkinson's disease patients with mild cognitive impairment analyzed via VBM technology.
    Gao Y; Nie K; Huang B; Mei M; Guo M; Xie S; Huang Z; Wang L; Zhao J; Zhang Y; Wang L
    Neurosci Lett; 2017 Sep; 658():121-132. PubMed ID: 28823894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visual Dysfunction Predicts Cognitive Impairment and White Matter Degeneration in Parkinson's Disease.
    Zarkali A; McColgan P; Leyland LA; Lees AJ; Weil RS
    Mov Disord; 2021 May; 36(5):1191-1202. PubMed ID: 33421201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal thalamic white and grey matter changes associated with visual hallucinations in Parkinson's disease.
    Zarkali A; McColgan P; Leyland LA; Lees AJ; Weil RS
    J Neurol Neurosurg Psychiatry; 2022 Feb; 93(2):169-179. PubMed ID: 34583941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex effects on brain structure in de novo Parkinson's disease: a multimodal neuroimaging study.
    Tremblay C; Abbasi N; Zeighami Y; Yau Y; Dadar M; Rahayel S; Dagher A
    Brain; 2020 Oct; 143(10):3052-3066. PubMed ID: 32980872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gray and white matter imaging: A biomarker for cognitive impairment in early Parkinson's disease?
    Duncan GW; Firbank MJ; Yarnall AJ; Khoo TK; Brooks DJ; Barker RA; Burn DJ; O'Brien JT
    Mov Disord; 2016 Jan; 31(1):103-10. PubMed ID: 26202802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibre-specific white matter reductions in Alzheimer's disease and mild cognitive impairment.
    Mito R; Raffelt D; Dhollander T; Vaughan DN; Tournier JD; Salvado O; Brodtmann A; Rowe CC; Villemagne VL; Connelly A
    Brain; 2018 Mar; 141(3):888-902. PubMed ID: 29309541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tracking Cortical Changes Throughout Cognitive Decline in Parkinson's Disease.
    Filippi M; Canu E; Donzuso G; Stojkovic T; Basaia S; Stankovic I; Tomic A; Markovic V; Petrovic I; Stefanova E; Kostic VS; Agosta F
    Mov Disord; 2020 Nov; 35(11):1987-1998. PubMed ID: 32886420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls.
    Burton EJ; McKeith IG; Burn DJ; Williams ED; O'Brien JT
    Brain; 2004 Apr; 127(Pt 4):791-800. PubMed ID: 14749292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson's disease longitudinally.
    Hanganu A; Bedetti C; Degroot C; Mejia-Constain B; Lafontaine AL; Soland V; Chouinard S; Bruneau MA; Mellah S; Belleville S; Monchi O
    Brain; 2014 Apr; 137(Pt 4):1120-9. PubMed ID: 24613932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. White matter abnormalities in Parkinson's disease patients with glucocerebrosidase gene mutations.
    Agosta F; Kostic VS; Davidovic K; Kresojević N; Sarro L; Svetel M; Stanković I; Comi G; Klein C; Filippi M
    Mov Disord; 2013 Jun; 28(6):772-8. PubMed ID: 23418083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atomoxetine restores the response inhibition network in Parkinson's disease.
    Rae CL; Nombela C; Rodríguez PV; Ye Z; Hughes LE; Jones PS; Ham T; Rittman T; Coyle-Gilchrist I; Regenthal R; Sahakian BJ; Barker RA; Robbins TW; Rowe JB
    Brain; 2016 Aug; 139(Pt 8):2235-48. PubMed ID: 27343257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal Lobe and Frontal-Subcortical Dissociations in Non-Demented Parkinson's Disease with Verbal Memory Impairment.
    Tanner JJ; Mareci TH; Okun MS; Bowers D; Libon DJ; Price CC
    PLoS One; 2015; 10(7):e0133792. PubMed ID: 26208170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two-step process.
    González-Redondo R; García-García D; Clavero P; Gasca-Salas C; García-Eulate R; Zubieta JL; Arbizu J; Obeso JA; Rodríguez-Oroz MC
    Brain; 2014 Aug; 137(Pt 8):2356-67. PubMed ID: 24951642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroimaging correlates of cognitive impairment and dementia in Parkinson's disease.
    Mak E; Su L; Williams GB; O'Brien JT
    Parkinsonism Relat Disord; 2015 Aug; 21(8):862-70. PubMed ID: 26004683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gray and White Matter Contributions to Cognitive Frontostriatal Deficits in Non-Demented Parkinson's Disease.
    Price CC; Tanner J; Nguyen PT; Schwab NA; Mitchell S; Slonena E; Brumback B; Okun MS; Mareci TH; Bowers D
    PLoS One; 2016; 11(1):e0147332. PubMed ID: 26784744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropsychiatric complications and neuroimaging characteristics after deep brain stimulation surgery for Parkinson's disease.
    Radziunas A; Deltuva VP; Tamasauskas A; Gleizniene R; Pranckeviciene A; Surkiene D; Bunevicius A
    Brain Imaging Behav; 2020 Feb; 14(1):62-71. PubMed ID: 30267364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
    Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
    Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations of mean diffusivity in brain white matter and deep gray matter in Parkinson's disease.
    Kim HJ; Kim SJ; Kim HS; Choi CG; Kim N; Han S; Jang EH; Chung SJ; Lee CS
    Neurosci Lett; 2013 Aug; 550():64-8. PubMed ID: 23831353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.